Micron Technology, Inc. vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Micron Technology, Inc. trades at $1,057.06 (market cap $1.17T), while Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B). The key difference: Micron Technology, Inc. is far larger — about 672.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| MU | NUVB | |
|---|---|---|
Market Cap | $1.17T | $1.74B |
Volume | 29,425,906 | 9,289,619 |
Sector | Technology | Health |
52-Week High | $1.21K | $9.54 |
52-Week Low | $181.60 | $3.41 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $1.13T | $1.33B |
Dividend Yield | 0.06% | — |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,088, up 4.06% today, reflecting strong momentum amid a bullish technical outlook. The stock shows robust fundamentals with a P/E of 14.64, net income margin of 63.8%, and three consecutive quarterly earnings beats. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus favoring Buy ratings (82.85%) and a $1,590 price target. Key risks include cyclical memory pricing and slowing growth projections, but institutional sentiment and cash flow trends support upside potential for investors seeking AI-driven semiconductor exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →